Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roseomonas mucosa in Atopic Dermatitis
NCT03018275Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of roseomonas mucosa in atopic dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: SCORing Atopic Dermatitis at 16 months and Adverse Events at 16 months. Started Apr 2017; status: completed.
02
Drugs
roseomonas mucosa
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03018275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018275.